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PreviewsThe Bad Seed in
Alzheimer’s Disease
In this issue of Neuron, McGowan et al. report on a
new mouse model of amyloid deposition as occurs in
Alzheimer’s disease. Unlike previous models in which
overexpression of the amyloid precursor protein re-
sults in amyloid plaque formation, McGowan et al.
have produced mice that overexpress only A40 or
A42 and prove that A42 is critical for the formation
of amyloid deposits in vivo.
For two decades scientists have known that the amy-
loid β (Aβ) peptide is the principal component of amy-
loid plaques found in Alzheimer’s disease (AD) brain
(Glenner and Wong, 1984). Numerous molecular and
genetic studies have subsequently given rise to what is
now known as the amyloid cascade hypothesis (Hardy
and Selkoe, 2002). The normally soluble Aβ peptide is
proteolytically processed from a larger protein termed
the amyloid β precursor protein (APP) and can be from
38 to 43 amino acids in length due to imprecise γ-secre-
tase cleavage, with the predominant species being 40
or 42 amino acids in length. Subsequently, mutations
were discovered in APP, or in components of γ-secre-
tase (presenilins) responsible for the processing of APP,
that are responsible for rare early-onset, familial forms
of AD. These APP or presenilin mutations share the
common feature of causing an increase in all Aβ spe-
cies or a relative increase in the level of Aβ42, which is
known to be more fibrillogenic than the slightly shorter
Aβ40 peptide in vitro. In addition, assessment of human
brain and cerebral vessels shows that Aβ42 appears to
deposit prior to Aβ40 (Gravina et al., 1995; Iwatsubo et
al., 1994). Transgenic mouse models of AD have been
generated by overexpression of human APP harboring
assorted familial AD mutations under control of various
promoters that result in high levels of brain expression,
such as the Tg2576 model (Hsiao et al., 1996) used by
McGowan et al. However, these models always gener-
ate both Aβ40 and Aβ42 at varying ratios, and thus de-
finitive proof of whether a specific species of Aβ such
as Aβ42 is responsible or required for seeding the for-
mation of amyloid plaques in vivo has either remained
unanswered or speculative.
In this issue of Neuron, Todd Golde and colleagues
(McGowan et al., 2005) have provided strong evidence
that Aβ42 is necessary for the formation of amyloid
plaques in vivo. They have created mice that express
only Aβ40 or Aβ42 (and not APP) by using a clever
molecular trick borrowed from the study of another un-
related cerebral amyloidosis termed Familial British De-
mentia (Kim et al., 1999; Vidal et al., 1999). Mice ex-
pressing only Aβ42 have substantial deposition of
amyloid in both parenchymal plaques as well as in the
walls of brain arterioles, termed cerebral amyloid angio-
pathy (CAA). In contrast, mice expressing only Aβ40 de-
velop no detectable amyloid deposits despite producingsubstantially higher Aβ levels than the Aβ42-expressing
mice. Additionally, they crossed the Aβ42-expressing
mice with the Tg2576 mouse model of AD. These bi-
genic Aβ42-Tg2576 mice have a massive increase in
the amount of amyloid that is deposited in the brain.
The amount of Aβ deposited is substantially more than
a mere additive effect, suggesting that an increase in
Aβ42 levels alone can drive the formation of amyloid.
The small, lingering issue of the contribution of endoge-
nous murine Aβ40 or Aβ42 can be addressed in future
studies using APP knockout mice.
Further examination of the bigenic Aβ42-Tg2576
mice could be very important for elucidating the issue
of whether Aβ will deposit in different ratios in brain
parenchymal tissue versus in vessels as CAA. Recently,
Herzig et al. reported that APP transgenic mice ex-
pressing a mutation within the Aβ coding region itself
give rise to almost entirely CAA instead of parenchymal
plaques. This shift in deposition from parenchyma to the
cerebral vasculature is likely due to a large increase in the
ratio of Aβ40 to Aβ42. If a high ratio of Aβ40 to Aβ42
favors CAA, then bigenic Aβ42-Tg2576 mice should have
a lower ratio of CAA to parenchymal plaques. Likewise,
crossing Aβ40-expressing to Aβ42-expressing mice
would be hypothesized to result in a higher ratio of CAA
to parenchymal plaques.
These findings not only provide a definitive under-
standing of the precipitating pathogenic molecule in
AD, but they also allow the pursuit of more targeted
therapies. Having the knowledge that Aβ42 is neces-
sary for initiating amyloid formation in vivo allows for
therapies that specifically target only this form as op-
posed to other forms of Aβ, such as Aβ40, which may
be potentially important given that we know very little
about the endogenous function of Aβ. Some potential
therapeutics such as nonsteroidal anti-inflammatory
drugs (NSAIDS) and HMG-CoA reductase inhibitors
(statins) have as yet unclear mechanisms of action. This
new model allows for specific testing of whether these
or other potential therapeutics work by inhibiting or al-
tering the ability of secretases to cleave APP or by
other biological actions once the Aβ peptide has been
generated.
Apolipoprotein E (apoE) remains the only proven ge-
netic risk factor for AD in humans (Strittmatter and
Roses, 1995), and AD mouse models lacking endoge-
nous apoE have greatly reduced Aβ deposition, with
almost no deposits of the toxic fibrillar variety, i.e., thio-
flavine-S, Congo red positive (Bales et al., 2002). ApoE
is an extracellular chaperone for the Aβ peptide and is
possibly more effective in transporting Aβ40 rather than
Aβ42. Recent experiments demonstrate that apoE4 ex-
pression results in a higher ratio of Aβ40/42 and a
marked increase in the ratio of CAA to parenchymal
plaques (Fryer et al., 2005). Crossing the Aβ42 and
combined Aβ42/Aβ40-expressing mice to apoE knock-
out mice and mice expressing human apoE isoforms
would further our understanding of the role of apoE in
the metabolism of Aβ and the pathogenesis of AD.
Many AD mouse models have subtle cognitive and
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168synaptic deficits long before the formation amyloid de-
posits, possibly due to overexpression of APP or higher
levels of soluble Aβ. Overexpression of human APP
leads not only to increased levels of Aβ but also to an
increase in a variety of APP C- and N-terminal frag-
ments that can have biological effects. Whether soluble
Aβ plays a role in these early deficits found in these
models prior to Aβ aggregation has not been defini-
tively answered. The authors report that their new
model has no obvious behavioral abnormalities, al-
though the behavioral abnormalities observed in other
AD mouse models thus far require testing in complex
learning and memory paradigms to fully appreciate (Ja-
nus and Westaway, 2001). Should the Aβ42-overex-
pressing mice develop age- and amyloid-dependent
cognitive decline, they will prove extremely valuable in
further experiments to specifically test the role of solu-
ble and insoluble forms of Aβ in both neurodegenera-
tion and cognition. Those interested in Aβ metabolism
should find these mice very useful, and we anxiously
await the studies that will stem from the use of these
new mouse models.
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